Transaction in Own Shares

Summary by AI BETAClose X

Hikma Pharmaceuticals Plc has purchased a total of 1,051,214 ordinary shares during the disclosure period from March 16 to March 20, 2026, as part of its $250 million share repurchase program. The purchases were made on various trading venues, with the highest volume of shares, 384,778, bought on the London Stock Exchange on March 19 at a volume-weighted average price of 1,237.41 pence. Since the program's inception on February 26, 2026, Hikma has repurchased 3,077,665 shares for £38.4 million, and these shares are intended for cancellation.

Disclaimer*

UK 100

Latest directors dealings